VJHemOnc is committed to improving our service to you

ASH 2019 | IMGN632: a novel CD123 ADC for R/R AML and BPDCN

VJHemOnc is committed to improving our service to you

Naval Daver

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the phase I study (NCT03386513) investigating the novel CD123-targeting antibody-drug conjugate IMGN632, which holds promise for treating R/R acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN), and other CD123-positive malignancies. Dr Daver highlights how this agent will be moving forwards, and discusses the combinations that are planned. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter